Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)

Anika Therapeutics has reported Liabilities from Discontinued Operations over the past 2 years, most recently at 659000.0 for Q4 2024.

Quarterly Liabilities from Discontinued Operations fell 33.37% to 659000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 659000.0 through Dec 2024, down 33.37% year-over-year, with the annual reading at 659000.0 for FY2024, 33.37% down from the prior year.
Liabilities from Discontinued Operations was 659000.0 for Q4 2024 at Anika Therapeutics, down from 989000.0 in the prior quarter.
Over five years, Liabilities from Discontinued Operations peaked at 989000.0 in Q4 2023 and troughed at 659000.0 in Q4 2024.